1/2
04:12 am
imvt
Immunovant price target lowered to $45 from $47 at Wells Fargo [Yahoo! Finance]
Low
Report
Immunovant price target lowered to $45 from $47 at Wells Fargo [Yahoo! Finance]
12/30
10:38 am
imvt
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth [Yahoo! Finance]
Low
Report
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth [Yahoo! Finance]
12/19
09:59 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its price target lowered by analysts at Wells Fargo & Company from $47.00 to $45.00. They now have an "overweight" rating on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its price target lowered by analysts at Wells Fargo & Company from $47.00 to $45.00. They now have an "overweight" rating on the stock.
12/11
06:38 am
imvt
FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial [Yahoo! Finance]
Low
Report
FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial [Yahoo! Finance]
11/13
09:45 am
imvt
Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, 2024
Medium
Report
Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, 2024
11/8
11:57 am
imvt
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus [Yahoo! Finance]
Low
Report
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus [Yahoo! Finance]
11/8
08:46 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
11/7
06:30 am
imvt
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
Low
Report
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
10/29
06:30 am
imvt
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
Low
Report
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
10/14
02:58 pm
imvt
Immunovant: Switching Lead Candidates Increases Risk [Seeking Alpha]
Low
Report
Immunovant: Switching Lead Candidates Increases Risk [Seeking Alpha]
10/10
09:36 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $36.00 price target on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $36.00 price target on the stock.
10/9
08:40 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its price target raised by analysts at Oppenheimer Holdings Inc. from $47.00 to $53.00. They now have an "outperform" rating on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its price target raised by analysts at Oppenheimer Holdings Inc. from $47.00 to $53.00. They now have an "outperform" rating on the stock.